or Try an Advanced Search...

    Dystrophy Stocks List

    Symbol Grade Name % Change
    DYN B Dyne Therapeutics, Inc. 0.57
    SRPT B Sarepta Therapeutics, Inc. -0.79
    IONS B Ionis Pharmaceuticals, Inc. -1.15
    SMMT B Summit Therapeutics plc 4.36
    TVTX B Travere Therapeutics, Inc. 0.73
    PTCT C PTC Therapeutics, Inc. 1.93
    BNTC C Benitec Biopharma Limited 3.92
    TRDA D Entrada Therapeutics, Inc. 0.49
    ELMD D Electromed, Inc. -5.85
    BLUE D bluebird bio, Inc. -0.90
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Medical Devices
    Related Stock Lists: Muscular Dystrophy Biopharmaceutical Biotechnology Duchenne Muscular Dystrophy Medicine Disease Duchenne Genetic Genealogy Medical Genetics Biology Myotonic Dystrophy Rare Diseases Spinal Muscular Atrophy Antisense RNA Cancer Cystic Fibrosis Drug Discovery Gene Expression Genetics Hepatitis B

    Related ETFs - A few ETFs which own one or more of the above listed Dystrophy stocks.

    Symbol Grade Name Weight
    IBRN C iShares Neuroscience and Healthcare ETF 13.79
    PINK A Simplify Health Care ETF 10.39
    BTEC B Principal Healthcare Innovators Index ETF 7.48
    BBP B BioShares Biotechnology Products Fund 7.17
    LABD F Direxion Daily S&P Biotech Bear 3X Shares 6.9
    View all Dystrophy ETFs...
    Compare ETFs
    Compare BBP to LABD Compare IBRN to LABD Compare PINK to BTEC

        Dystrophy Stocks Recent News

        Date Stock Title
        Jul 1 PTCT PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
        Jul 1 BNTC Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
        Jun 28 PTCT Biggest stock movers today: PLUG, NKE, DJT, and more
        Jun 28 PTCT PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
        Jun 28 PTCT PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
        Jun 28 PTCT PTC drops as EU panel declines to recommend Translarna marketing renewal
        Jun 28 PTCT CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
        Jun 27 SMMT Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
        Jun 27 BLUE bluebird bio's Flight Through Financial Fog And Fierce Rivals
        Jun 27 SRPT Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
        Jun 27 TRDA With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors
        Jun 26 IONS FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
        Jun 26 SRPT Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
        Jun 26 SRPT Sarepta cut to Neutral at Citi on risks to valuation
        Jun 26 SRPT Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
        Jun 25 IONS Ionis gains as anti-lipid therapy undergoes FDA priority review
        Jun 25 IONS Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
        Jun 25 IONS Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Medical Devices
        Related Stock Lists: Muscular Dystrophy Biopharmaceutical Biotechnology Duchenne Muscular Dystrophy Medicine Disease Duchenne Genetic Genealogy Medical Genetics Biology Myotonic Dystrophy Rare Diseases Spinal Muscular Atrophy Antisense RNA Cancer Cystic Fibrosis Drug Discovery Gene Expression Genetics Hepatitis B
        Dystrophy

        Dystrophy is the degeneration of tissue, due to disease or malnutrition, most likely due to heredity.

        More about Dystrophy
        Browse All Tags